HTB | HIV i-Base

HTB May 2022 (2 May 2022)

Featured HTB May 2022 (2 May 2022) 2 May 2022. Related: Editorial.
Featured CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP 1 April 2021. Related: Conference reports, Antiretrovirals, CROI 28 (virtual) 2021.
Featured In memory: Timothy Ray Brown – the Berlin patient, the first person to be cured of HIV 14 October 2020. Related: In memory.
Seven cases of monkeypox virus in the UK from 2018 to 2021 25 May 2022. Related: Early access, Coinfections and complications.
Risk of monkeypox becoming endemic in Europe: ECDC assessment 23 May 2022. Related: Early access, Coinfections and complications.
Monkeypox cases in gay men in the UK: BHIVA and ECDC rapid statements 19 May 2022. Related: Early access, Coinfections and complications.
Implications of SARS-CoV-2 in gut tissue for transmission of COVID-19 and long COVID 19 May 2022. Related: Early access, Coinfections and complications, COVID-19.
Lenacapavir in MDR HIV: phase 3 results of CAPELLA study published 12 May 2022. Related: Early access, Antiretrovirals.
Family of Greek activist Zak Kostopoulos decry minimal sentence given to his killers 5 May 2022. Related: Other news.
Sending unused meds to Ukraine: emergency appeal 2 May 2022. Related: Editorial.
Organisations to support Ukraine 2 May 2022. Related: Editorial.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports 2 May 2022. Related: Conference reports, Conference index, CROI 29 (Retrovirus) 2022.
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART 2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, CROI 29 (Retrovirus) 2022.
CROI 2022: Other COVID-19 studies 2 May 2022. Related: Conference reports, Coinfections and complications, COVID-19.
FDA approves dispersible dolutegravir/abacavir/3TC for children 2 May 2022. Related: Antiretrovirals.
Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits 2 May 2022. Related: Antiretrovirals, Treatment access.
Asymptomatic COVID-19 is common in people living with HIV 2 May 2022. Related: Coinfections and complications, COVID-19: HIV and COVID-19 coinfection, COVID-19.
Longest COVID-19 infection lasted 505 days in an immunocompromised person in London 2 May 2022. Related: Coinfections and complications, COVID-19: HIV and COVID-19 coinfection, COVID-19: pathogenesis, COVID-19.
Herd immunity unlikely to control COVID-19: opinion article from US NIAID 2 May 2022. Related: Coinfections and complications, COVID-19: transmission & prevention, COVID-19.
The challenges of prioritising access to molnupiravir and nirmatrelvir–ritonavir for COVID-19 2 May 2022. Related: Coinfections and complications, COVID-19: complications, COVID-19.
Increased risk of blood clots after COVID-19: higher with underlying conditions and more severe symptoms 2 May 2022. Related: Coinfections and complications, COVID-19: complications, COVID-19.
Two new platform vaccines against COVID-19 report phase 3 results 2 May 2022. Related: Coinfections and complications, Other news, COVID-19: vaccine research, COVID-19.
A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton 2 May 2022. Related: HIV prevention and transmission.
Zimbabwe decriminalises HIV transmission 2 May 2022. Related: HIV prevention and transmission, Other news.
Community webinar series on HIV cure-related cell and gene therapy 2 May 2022. Related: Cure research.
HTB: no. 5 (2 May 2022) PDF downloads 2 May 2022. Related: PDFs.
Future meetings and webinars 2022 2 May 2022. Related: Future meetings.
HTB April 2022 (1 April 2022) 1 April 2022. Related: Editorial.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports 1 April 2022. Related: Conference reports, CROI 29 (Retrovirus) 2022.
CROI 2022: Webcasts now online and open access 1 April 2022. Related: Conference reports, CROI 29 (Retrovirus) 2022.
CROI 2022: Islatravir studies for HIV treatment and PrEP 1 April 2022. Related: Conference reports, Antiretrovirals, CROI 29 (Retrovirus) 2022.
CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART 1 April 2022. Related: Conference reports, Coinfections and complications, CROI 29 (Retrovirus) 2022.
CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa 1 April 2022. Related: Conference reports, Coinfections and complications, CROI 29 (Retrovirus) 2022.
CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses 1 April 2022. Related: Conference reports, Coinfections and complications, COVID-19: long COVID, COVID-19, CROI 29 (Retrovirus) 2022.
CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART 1 April 2022. Related: Conference reports, Coinfections and complications, CROI 29 (Retrovirus) 2022.
CROI 2022: UK study shows PEP is started earlier using home starter packs 1 April 2022. Related: Conference reports, HIV prevention and transmission, CROI 29 (Retrovirus) 2022.
CROI 2022: Summary of 14 key studies on HIV and liver disease 1 April 2022. Related: Conference reports, Hepatitis coinfection.
CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs 1 April 2022. Related: Conference reports, Cure research.
US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents 1 April 2022. Related: Antiretrovirals.
HIV vaccine study using mRNA technology starts in the US 1 April 2022. Related: HIV prevention and transmission.
South Africa approves dapivirine vaginal ring for HIV prevention 1 April 2022. Related: HIV prevention and transmission.
BHIVA statement on fourth vaccine dose for people living with HIV in the UK 1 April 2022. Related: COVID-19: HIV and COVID-19 coinfection.
Temporary protection against omicron needs mRNA booster: limited data for those at highest risk 1 April 2022. Related: COVID-19: vaccine research, COVID-19.
HTB: no. 4 (1 April 2022) PDF downloads 1 April 2022. Related: PDFs.
Efficacy of mRNA vaccines in people with HIV or solid transplant recipients 8 March 2022. Related: COVID-19: vaccine research, COVID-19.
HTB March 2022 (1 March 2022) 1 March 2022. Related: Editorial.
EACS statement on the war in Ukraine 1 March 2022. Related: Editorial, Special reports.
Organisations to support the crisis in Ukraine 1 March 2022. Related: Editorial, Special reports.
29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports 1 March 2022. Related: Conference reports, Conference index, CROI 29 (Retrovirus) 2022.
CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies 1 March 2022. Related: Conference reports, Antiretrovirals, CROI 29 (Retrovirus) 2022.
CROI 2022: Injectable CAB/RPV-LA results after three years follow-up 1 March 2022. Related: Conference reports, Antiretrovirals, CROI 29 (Retrovirus) 2022.
CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study 1 March 2022. Related: Conference reports, Antiretrovirals, CROI 29 (Retrovirus) 2022.